Sigilon Therapeutics (NASDAQ:SGTX) Trading Up 6%

Sigilon Therapeutics, Inc. (NASDAQ:SGTXGet Rating) was up 6% during trading on Friday . The company traded as high as $0.54 and last traded at $0.53. Approximately 69,137 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 80,755 shares. The stock had previously closed at $0.50.

Sigilon Therapeutics Price Performance

The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 0.29. The business’s fifty day moving average is $0.54 and its 200 day moving average is $0.73. The firm has a market capitalization of $17.17 million, a P/E ratio of -0.26 and a beta of 0.25.

Institutional Trading of Sigilon Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SGTX. Renaissance Technologies LLC raised its holdings in shares of Sigilon Therapeutics by 131.8% in the 1st quarter. Renaissance Technologies LLC now owns 275,600 shares of the company’s stock worth $405,000 after purchasing an additional 156,689 shares in the last quarter. State Street Corp raised its holdings in shares of Sigilon Therapeutics by 26.7% during the first quarter. State Street Corp now owns 330,471 shares of the company’s stock valued at $486,000 after acquiring an additional 69,662 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Sigilon Therapeutics during the second quarter valued at approximately $256,000. 52.73% of the stock is currently owned by institutional investors.

Sigilon Therapeutics Company Profile

(Get Rating)

Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.

Featured Stories

Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with's FREE daily email newsletter.